These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1489 related articles for article (PubMed ID: 33723016)

  • 21. Escalating SARS-CoV-2 specific humoral immune response in rheumatoid arthritis patients and healthy controls.
    Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Gunkl-Toth L; Merkely B; Nagy G
    Front Immunol; 2024; 15():1397052. PubMed ID: 38911866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection.
    Movsisyan M; Truzyan N; Kasparova I; Chopikyan A; Sawaqed R; Bedross A; Sukiasyan M; Dilbaryan K; Shariff S; Kantawala B; Hakobjanyan G; Petrosyan G; Hakobyan A; Yenkoyan K
    Sci Rep; 2024 Jun; 14(1):13417. PubMed ID: 38862731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD8
    Lineburg KE; Grant EJ; Swaminathan S; Chatzileontiadou DSM; Szeto C; Sloane H; Panikkar A; Raju J; Crooks P; Rehan S; Nguyen AT; Lekieffre L; Neller MA; Tong ZWM; Jayasinghe D; Chew KY; Lobos CA; Halim H; Burrows JM; Riboldi-Tunnicliffe A; Chen W; D'Orsogna L; Khanna R; Short KR; Smith C; Gras S
    Immunity; 2021 May; 54(5):1055-1065.e5. PubMed ID: 33945786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
    Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
    J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment.
    Kim N; Lee JM; Oh EJ; Jekarl DW; Lee DG; Im KI; Cho SG
    Front Immunol; 2021; 12():751869. PubMed ID: 35003063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
    Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
    Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients.
    Zeng F; Wu M; Wang J; Li J; Hu G; Wang L
    J Med Virol; 2021 Dec; 93(12):6506-6511. PubMed ID: 34170519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence.
    Boppana S; Qin K; Files JK; Russell RM; Stoltz R; Bibollet-Ruche F; Bansal A; Erdmann N; Hahn BH; Goepfert PA
    PLoS Pathog; 2021 Jul; 17(7):e1009761. PubMed ID: 34270631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19-convalescent individuals.
    Li M; Liu J; Lu R; Zhang Y; Du M; Xing M; Wu Z; Kong X; Zhu Y; Zhou X; Hu L; Zhang C; Zhou D; Jin X
    J Allergy Clin Immunol; 2022 Apr; 149(4):1225-1241. PubMed ID: 35074422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients.
    Melin J; Svensson MK; Albinsson B; Winqvist O; Pauksens K
    BMC Immunol; 2021 Oct; 22(1):70. PubMed ID: 34666683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs.
    Thura M; Sng JXE; Ang KH; Li J; Gupta A; Hong JM; Hong CW; Zeng Q
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34519332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity.
    Lehmann AA; Kirchenbaum GA; Zhang T; Reche PA; Lehmann PV
    Front Immunol; 2021; 12():635942. PubMed ID: 34127926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents.
    Koerber N; Priller A; Yazici S; Bauer T; Cheng CC; Mijočević H; Wintersteller H; Jeske S; Vogel E; Feuerherd M; Tinnefeld K; Winter C; Ruland J; Gerhard M; Haller B; Christa C; Zelger O; Roggendorf H; Halle M; Erber J; Lingor P; Keppler O; Zehn D; Protzer U; Knolle PA
    Nat Commun; 2022 Jan; 13(1):153. PubMed ID: 35013191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals.
    Johansson AM; Malhotra U; Kim YG; Gomez R; Krist MP; Wald A; Koelle DM; Kwok WW
    PLoS Pathog; 2021 Dec; 17(12):e1010203. PubMed ID: 34965282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.
    Kim JY; Kwon JS; Bae S; Cha HH; Lim JS; Kim MC; Chung JW; Park SY; Lee MJ; Kim BN; Jung J; Kim MJ; Shin EC; Kim SH
    Am J Trop Med Hyg; 2021 Jun; 105(2):395-400. PubMed ID: 34143752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets.
    Dugan HL; Stamper CT; Li L; Changrob S; Asby NW; Halfmann PJ; Zheng NY; Huang M; Shaw DG; Cobb MS; Erickson SA; Guthmiller JJ; Stovicek O; Wang J; Winkler ES; Madariaga ML; Shanmugarajah K; Jansen MO; Amanat F; Stewart I; Utset HA; Huang J; Nelson CA; Dai YN; Hall PD; Jedrzejczak RP; Joachimiak A; Krammer F; Diamond MS; Fremont DH; Kawaoka Y; Wilson PC
    Immunity; 2021 Jun; 54(6):1290-1303.e7. PubMed ID: 34022127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.
    Holenya P; Lange PJ; Reimer U; Woltersdorf W; Panterodt T; Glas M; Wasner M; Eckey M; Drosch M; Hollidt JM; Naumann M; Kern F; Wenschuh H; Lange R; Schnatbaum K; Bier FF
    Eur J Immunol; 2021 Jul; 51(7):1839-1849. PubMed ID: 33772767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
    Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
    Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 75.